Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB01186_DB01624_nanopub.RAOZS3eUvaPIEhhg40i5CeyoWLQi5WqzopxBXOcJbmK18#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB01186_DB01624 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01186_DB01624 label "DDI between Pergolide and Zuclopenthixol - Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and pergolide, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed. Pergolide, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if pergolide is initiated, discontinued or dose changed. [drugbank_resource:DB01186_DB01624]" assertion.
- drugbank_resource:DB01186_DB01624 identifier "drugbank_resource:DB01186_DB01624" assertion.
- drugbank_resource:DB01186_DB01624 title "DDI between Pergolide and Zuclopenthixol - Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and pergolide, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed. Pergolide, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if pergolide is initiated, discontinued or dose changed." assertion.
- drugbank:DB01186 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01186_DB01624 assertion.
- drugbank:DB01624 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01186_DB01624 assertion.